A Phase 4 interventional study of Rapid Diagnostics in Blood Stream Infections, Ventilator Associated Pneumonia and Healthcare Associated Infection, sponsored by National University of Singapore. Recruiting at 21 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by National University of Singapore · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
RAPID is an investigator initiated Phase 4, multinational, multicentre, open-label, randomised controlled superiority trial evaluating the clinical impact of rapid microbiological diagnostics combined with antimicrobial stewardship and early targeted antibiotic therapy compared with standard-of-care diagnostics and antibiotics.
Hospitalised adult patients with bloodstream infections, hospital-acquired pneumonia or ventilator-associated pneumonia are randomised in a 1:1 ratio to the intervention or control arm.
The main analysis population comprises patients with infections caused by Pseudomonas aeruginosa or carbapenem-resistant Enterobacterales. A secondary analysis population includes patients with infections caused by other specified multidrug-resistant Gram-negative organisms.
Patients will be randomised to either a control or intervention arm. Patients randomised to the intervention arm will have relevant specimens analysed by rapid microbiological diagnostics and will have early availability of ceftazidime-avibactam if appropriate. Patients randomised to the control arm, will have samples analysed by clinical microbiology laboratories using standard of care diagnostics. Antibiotics will be available to these patients as per usual institutional practice.
The primary outcome is a composite of all-cause mortality or absence of improvement in Sequential Organ Failure Assessment (SOFA) score at Day 14 following the index culture.
The RAPID trial integrates rapid molecular diagnostics with locally adapted antimicrobial stewardship guidelines to facilitate timely identification of Gram-negative pathogens, detection of antimicrobial resistance genes and appropriate antibiotic selection.
In the intervention arm, positive blood cultures will undergo testing using the BioFire Blood Culture Identification 2 (BCID2) Panel, while respiratory specimens from patients with hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP) will be tested using the BioFire FilmArray Pneumonia Panel or Pneumonia Plus Panel. Rapid diagnostic testing will be initiated within four hours of Gram-negative bacilli being observed on Gram stain, alongside conventional microbiological testing. Clinicians will receive guidance on interpreting resistance gene results and selecting antibiotics according to locally adapted antimicrobial stewardship protocols. Ceftazidime-avibactam will be available for patients with Pseudomonas aeruginosa or Enterobacterales with detected carbapenemase genes, subject to predefined eligibility criteria and local regulatory approval. Antibiotic treatment may subsequently be modified based on conventional susceptibility testing and clinical judgement.
In the control arm, microbiological investigations and antibiotic treatment will follow standard institutional practices, with antibiotic selection determined by the treating clinicians.
Study population assignment will be based on conventional microbiological identification and antimicrobial susceptibility testing in both arms. The main analysis population will comprise patients with bloodstream infections, HAP or VAP caused by Pseudomonas aeruginosa or carbapenem-resistant Enterobacterales. The secondary analysis population will include patients with infections caused by ceftriaxone/cefotaxime/ceftazidime-resistant Enterobacterales, carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex or Stenotrophomonas maltophilia. Patients in the secondary population will receive antibiotics according to locally adapted antimicrobial stewardship guidelines rather than protocol-directed ceftazidime-avibactam.
Participants will be followed for 60 days following the index culture, with assessments of clinical outcomes, mortality, antibiotic utilisation, microbiological outcomes, antimicrobial resistance and functional status. Repeat microbiological cultures will be performed to assess bacterial persistence, and initial bacterial isolates will undergo antimicrobial susceptibility testing and whole-genome sequencing at a central laboratory.
420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.
This study's planned enrollment of 1,526 is above the median of 115 across 276 interventional studies indexed under Pneumonia, Ventilator-Associated.
Browse Pneumonia, Ventilator-Associated studies →National University of Singapore is the lead sponsor of 212 studies on the registry; 50 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Oct 22, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adult patients aged 18 years or older (21 years or older in Singapore) who meet at least one of the following criteria:
For randomisation, all of the following criteria must be fulfilled:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rapid microbiological diagnostics using the BioFire BCID2 Panel for bloodstream infections or BioFire FilmArray Pneumonia/Pneumonia Plus Panel for respiratory infections, combined with locally adapted antimicrobial stewardship and early targeted antibiotic therapy. Samples from patients randomised to the intervention arm will undergo the BioFire FilmArray systems. Patients will be then administered with the study drug, ceftazidime-avibactam when Pseudomonas aeruginosa or carbapenemase producing Enterobacterales detected. Appropriate antibiotic must be administered according to predefined antibiotic stewardship guidelines within 24 hours of the Gram stain being performed on the index specimen.
Diagnostic Test: Rapid Diagnostics
Standard-of-care microbiological diagnostics and antibiotic treatment according to local clinical practice and treating physician discretion. Patients randomised to the control arm, will have samples analysed by clinical microbiology laboratories using standard of care diagnostics. Antibiotics treatment will be administered as per usual institutional practice from hospital supplies.
Patients randomised to the intervention arm, will have the BioFire Blood Culture Identification 2 Panel (BCID2) used for positive blood cultures and/or the BioFire FilmArray Pneumonia plus PanelPneumonia Panel or Pneumonia plus Panel for respiratory tract specimens if having hospital-acquired pneumonia or ventilator-associated pneumonia. Rapid diagnostic testing must be initiated as soon as Gram-negative bacilli is detected on Gram stain, and appropriate antibiotic must be administered according to predefined antibiotic stewardship guidelines within 24 hours of the Gram stain being performed on the index respiratory or blood culture specimen, that defined entry into the trial. Standard of care diagnostics will also be used. Antibiotic guidelines will be provided to clinicians to aid interpretation of test results and treatment prescription. Ceftazidime-avibactam will be available for targeted use in patients with Pseudomonas aeruginosa or carbapenemase producing Enterobacterales.
Also known as: BioFire FilmArray BCID2, BioFire FilmArray Pneumonia Plus Panel, BioFire FilmArray Pneumonia Panel
Composite of All-Cause Mortality or Absence of SOFA Score Improvement at Day 14
Proportion of participants experiencing all-cause mortality within 14 days of the index blood or respiratory culture, or absence of improvement in Sequential Organ Failure Assessment (SOFA) score at Day 14. SOFA improvement is defined according to the prespecified baseline SOFA criteria in the study protocol.
Time frame: Day 14 following index culture.
Clinical Response at Day 7 and Day 14
Proportion of participants achieving clinical response at Day 7 and Day 14 following the index culture, assessed using clinical stability indicators, including temperature \<38°C for at least 48 hours and systolic blood pressure \>90 mmHg without inotropic support.
Time frame: Day 7 and Day 14 following index culture
All-Cause Mortality at Day 14, Day 28 and Day 60
Proportion of participants who die from any cause within 14, 28 and 60 days following collection of the index blood or respiratory culture specimen.
Time frame: Day 14, Day 28 and Day 60 following index culture
Functional Status and Health-Related Quality of Life
Functional status and health-related quality of life will be assessed using the Functional Bacteraemia and Infection Score (FBIS) and EuroQol 5-Dimension 3-Level questionnaire (EQ-5D-3L), respectively, at Day 14, Day 28 and Day 60 following the index culture.
Time frame: Day 14, Day 28 and Day 60 following index culture
Desirability of Outcome Ranking (DOOR) at Day 28
Participant outcomes will be assessed using a five-level Desirability of Outcome Ranking (DOOR) composite measure incorporating survival status at Day 28, absence of early clinical response and late infectious complications. Scores range from 1 to 5, with lower scores indicating more desirable outcomes.
Time frame: Day 28 following index culture
Implementation Costs and Health Economic Outcomes
Implementation costs will be evaluated using hospital and intensive care unit (ICU) length of stay within 60 days following randomisation. Within-trial and modelled economic evaluations will assess costs and health outcomes associated with rapid diagnostics and antimicrobial stewardship compared with standard care. Cost-effectiveness will be expressed using incremental cost-effectiveness ratios and net monetary benefits.
Time frame: Within 60 days following randomisation for within-trial resource utilisation; modelled time horizon to be confirmed.
Days Alive and Out of Hospital Within 60 Days
Number of days participants are alive and out of hospital during the 60-day period following the index culture.
Time frame: Up to Day 60 following index culture
Length of Intensive Care Unit Stay
Duration of intensive care unit (ICU) stay, measured in days, during the 60-day follow-up period.
Time frame: Up to Day 60 following index culture
Length of Hospital Stay
Duration of hospitalisation, measured in days, during the 60-day follow-up period.
Time frame: Up to Day 60 following index culture
Duration of Mechanical Ventilation
Total number of days participants require mechanical ventilation during the 60-day follow-up period
Time frame: Up to Day 60 following index culture
Type of Accommodation Upon Hospital Discharge
Type of accommodation or care setting to which participants are discharged following hospitalisation.
Time frame: At hospital discharge, assessed within 60 days following index culture
Persistence of Bacteraemia at Day 4
Proportion of participants with bloodstream infection who have persistent bacterial growth in repeat blood cultures collected on Day 4 following the index culture.
Time frame: Day 4 following index culture
Microbiological Growth in Respiratory Cultures at Day 7
Proportion of participants with hospital-acquired pneumonia or ventilator-associated pneumonia who have bacterial growth detected in repeat respiratory cultures collected on Day 7 following the index culture.
Time frame: Day 7 following index culture
Development of Resistance to Meropenem or Ceftazidime-Avibactam
Proportion of participants with bacterial isolates demonstrating development of resistance to meropenem or ceftazidime-avibactam during follow-up, as determined by antimicrobial susceptibility testing.
Time frame: Up to Day 28 following index culture
Incidence of Acute Kidney Injury
Proportion of participants developing acute kidney injury during the 28-day follow-up period.
Time frame: Up to Day 28 following index culture
Incidence of Clostridioides difficile Diarrhoea
Proportion of participants developing Clostridioides difficile-associated diarrhoea during the 28-day follow-up period.
Time frame: Up to Day 28 following index culture
Time From Index Culture to Active Antibiotic Therapy
Time elapsed, measured in hours, between collection of the index culture specimen and administration of the first antibiotic with activity against the causative pathogen.
Time frame: From index culture collection to initiation of active antibiotic therapy
Number of Days on Antibiotic Treatment Within 28 Days
Total number of days of antibiotic treatment administered to participants during the first 28 days following the index culture.
Time frame: Up to Day 28 following index culture
Antibiotic Treatment Modification Following Microbiological Diagnosis
Proportion of participants whose antibiotic treatment is modified within seven days following availability of microbiological diagnostic results.
Time frame: Within 7 days following microbiological diagnostic results
Time to Detection of Carbapenemase Production or Carbapenem Resistance
Time elapsed, measured in hours, between collection of the index specimen and reporting of carbapenemase production and/or carbapenem resistance in the causative bacterial isolate.
Time frame: From index specimen collection to reporting of microbiological results
Time to Detection of Third-Generation Cephalosporin Resistance
Time elapsed, measured in hours, between collection of the index specimen and reporting of resistance to ceftriaxone, cefotaxime or ceftazidime in Enterobacterales isolates.
Time frame: From index specimen collection to reporting of microbiological results
Time to Identification of Other Multidrug-Resistant Gram-Negative Pathogens
Time elapsed, measured in hours, between collection of the index specimen and identification of Acinetobacter baumannii-calcoaceticus complex or Stenotrophomonas maltophilia.
Time frame: From index specimen collection to reporting of microbiological results
Whole-Genome Sequencing of Causative Bacterial Isolates
Initial bacterial isolates collected from participants will undergo whole-genome sequencing at a central laboratory for genotypic characterisation of the causative pathogens.
Time frame: Baseline (index culture)
Plan to share: Yes — De-identified individual participant data underlying the results reported in the primary publication of the RAPID trial may be shared with qualified researchers following approval of a methodologically sound proposal, subject to applicable ethical, regulatory, institutional and contractual requirements.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Beginning 12 months after publication of the primary trial results and remaining available for 5 years.
Access criteria: Requests will be reviewed by the RAPID trial investigators and/or the relevant institutional data access authority. Approved researchers must enter into an appropriate data-sharing agreement.
No publications or documents are linked to this record.
Started Dec 2023 (actual). Primary completion is estimated for Oct 2027, 46 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Oct 2026 → Oct 2027 and completion Dec 2026 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pneumonia, Ventilator-Associated →
National University of Singapore →